This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US judge 'inclined' to sever Celonis claims from SAP patent counterclaims

( February 24, 2026, 19:12 GMT | Official Statement) -- MLex Summary: A California federal judge said he's "inclined" to grant Celonis's motion to sever its antitrust claims from SAP's patent infringement counterclaims. Celonis alleges that SAP engaged in anticompetitive conduct to prop up its process mining product, Signavio. SAP then filed US patent infringement claims against Celonis regarding software for enterprise-resource planning. In an order, US District Judge Vince Chhabria said the parties should be prepared to educate him at a hearing "on how similar the Delaware patent claims are to the counterclaims in this case." The judge said he is "also interested in learning whether there is any contemporaneous evidence to support SAP's apparent assertion that one of the reasons it engaged in the allegedly anticompetitive conduct towards Celonis was to protect SAP's patent rights." See full docket entry below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections